Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model.

Alzheimer's disease (AD) is the major age-dependent disease of the brain, but what instigates late-onset AD is not yet clear. Epidemiological, animal model, and cell biology findings suggest links between AD and diabetes. Although AD pathology is accelerated by diabetes in mice engineered to accumulate human-sequence amyloid-β (Aβ) peptides, they do not adequately model non-inherited AD. We investigated AD-type pathology induced solely by diabetes in genetically unmodified rabbits which generate human-sequence Aβ peptides. After 15 weeks, alloxan-treated diabetic rabbits with expected high blood glucose showed ~5-fold increase in Aβ40/Aβ42 in cortex and hippocampus, and significantly, generated Aβ-derived assemblies found in human AD. Deposits of these putative pathogenic toxins were detected by Aβ/Aβ oligomer antibodies in brain parenchyma and surrounding vasculature, also co-localizing with markedly elevated levels of RAGE. Soluble brain extracts showed diabetes-induced buildup of Aβ oligomers on dot-blots. Phospho-tau also was clearly elevated, overlapping with βIII-tubulin along neuronal tracts. Indications of retina involvement in AD led to examination of AD-type pathology in diabetic retinas and showed Aβ accumulation in ganglion and inner nuclear cell layers using Aβ/oligomer antibodies, and RAGE again was elevated. Our study identifies emergence of AD pathology in brain and retina as a major consequence of diabetes; implicating dysfunctional insulin signaling in late-onset AD, and a potential relationship between Aβ-derived neurotoxins and retinal degeneration in aging and diabetes, as well as AD. AD-type pathology demonstrated in genetically unmodified rabbits calls attention to the considerable potential of the model for investigation of AD pathogenesis, diagnostics, and therapeutics.

[1]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[3]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[4]  T. Holzman,et al.  β/A4‐evoked degeneration of differentiated SH‐SY5Y human neuroblastoma cells , 1994 .

[5]  S. M. de la Monte,et al.  Insulin resistance and Alzheimer's disease. , 2009, BMB reports.

[6]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[7]  T. Bliss,et al.  Long‐lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path , 1973, The Journal of physiology.

[8]  Suzanne Craft,et al.  Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation , 2005, Neurobiology of Aging.

[9]  C. Glabe Conformation-dependent antibodies target diseases of protein misfolding. , 2004, Trends in biochemical sciences.

[10]  M. Rowan,et al.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.

[11]  Christian Hölscher,et al.  Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. , 2011, Biochemical Society transactions.

[12]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Gandy,et al.  The role of cerebral amyloid β accumulation in common forms of Alzheimer disease , 2005 .

[14]  Yicheng Feng,et al.  Increased expression and local accumulation of the Prion Protein, Alzheimer Aβ peptides, superoxide dismutase 1, and Nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes , 2010, BMC Physiology.

[15]  Transgenic Models of Alzheimer’s Disease , 2001 .

[16]  K. Zahs,et al.  ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.

[17]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[18]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[19]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[20]  R. Munday,et al.  The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. , 1993, The Journal of endocrinology.

[21]  W. Engel,et al.  Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers , 2010, Acta Neuropathologica.

[22]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[23]  A. Zmijewska,et al.  Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.

[24]  A. Schmidt,et al.  The RAGE axis in early diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.

[25]  Alan W. Stitt,et al.  AGEs, RAGE, and Diabetic Retinopathy , 2011, Current diabetes reports.

[26]  Wei⁃qin Zhao,et al.  Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. , 2009, Biochimica et biophysica acta.

[27]  S. Kanba,et al.  Insulin resistance is associated with the pathology of Alzheimer disease , 2010, Neurology.

[28]  R. Martins,et al.  Insulin Effects on Glucose Metabolism, Memory, and Plasma Amyloid Precursor Protein in Alzheimer's Disease Differ According to Apolipoprotein‐E Genotype , 2000, Annals of the New York Academy of Sciences.

[29]  A. Chobanian,et al.  Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit. , 1991, Journal of lipid research.

[30]  John Hardy,et al.  Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. , 2005, The American journal of pathology.

[31]  D. Selkoe,et al.  Soluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway* , 2007, Journal of Biological Chemistry.

[32]  Colin L. Masters,et al.  Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  H. Mori,et al.  Absence of synaptophysin near cortical neurons containing oligomer Aβ in Alzheimer's disease brain , 2006, Journal of neuroscience research.

[34]  S. Little,et al.  Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. , 1991, Brain research. Molecular brain research.

[35]  S. Feinstein,et al.  Amyloid β-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation* , 2011, The Journal of Biological Chemistry.

[36]  B. Hyman,et al.  Transgenic models of Alzheimer’s disease: Learning from animals , 2005, NeuroRX.

[37]  D. Munoz,et al.  An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. , 2012, The Journal of clinical investigation.

[38]  M. Vestling,et al.  Amyloid-β Oligomer Specificity Mediated by the IgM Isotype – Implications for a Specific Protective Mechanism Exerted by Endogenous Auto-Antibodies , 2010, PloS one.

[39]  L. Frölich,et al.  Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. , 2009, Journal of Alzheimer's disease : JAD.

[40]  J. Götz,et al.  Experimental Diabetes Mellitus Exacerbates Tau Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2009, PloS one.

[41]  Christian Hölscher,et al.  The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[42]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[43]  C. Heizmann,et al.  Site-Specific Blockade of RAGE-Vd Prevents Amyloid-β Oligomer Neurotoxicity , 2008, The Journal of Neuroscience.

[44]  P. Worley,et al.  Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development , 2012, Neuropsychopharmacology.

[45]  W. Klein,et al.  Amyloid beta oligomers induce impairment of neuronal insulin receptors , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  K. Imahori,et al.  Amyloid β peptide induces cytoplasmic accumulation of amyloid protein precursor via tau protein kinase I/glycogen synthase kinase-3β in rat hippocampal neurons , 1995, Neuroscience Letters.

[47]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[48]  Xiaohua Douglas Zhang,et al.  Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic Disruption , 2009, The Journal of Biological Chemistry.

[49]  T Szkudelski,et al.  The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.

[50]  E. Masliah,et al.  Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.

[51]  K. Ono,et al.  Low‐n oligomers as therapeutic targets of Alzheimer’s disease , 2011, Journal of neurochemistry.

[52]  R. Martins,et al.  Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. , 1985, The EMBO journal.

[53]  C. Carlsson,et al.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[54]  K. Imahori,et al.  Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[56]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[57]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Ying Liu,et al.  Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes , 2011, The Journal of pathology.

[59]  Gianluigi Forloni,et al.  APP Transgenic Mice: Their Use and Limitations , 2011, NeuroMolecular Medicine.

[60]  J. Disterhoft,et al.  Connections of the caudal anterior cingulate cortex in rabbit: Neural circuitry participating in the acquisition of trace eyeblink conditioning , 2007, Neuroscience.

[61]  M. S. Alhamdani,et al.  Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. , 2006, Life sciences.

[62]  R. Raffa,et al.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? , 2011, British journal of clinical pharmacology.

[63]  Zina Kroner,et al.  The relationship between Alzheimer's disease and diabetes: Type 3 diabetes? , 2009, Alternative medicine review : a journal of clinical therapeutic.

[64]  Virginia M. Y. Lee,et al.  Molecular features of hypothalamic plaques in Alzheimer's disease. , 1991, The American journal of pathology.

[65]  K. Hsu,et al.  Insulin rescues amyloid β-induced impairment of hippocampal long-term potentiation , 2009, Neurobiology of Aging.

[66]  W. Klein,et al.  Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ* , 2009, The Journal of Biological Chemistry.

[67]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[68]  J. McArdle,et al.  Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus. , 2001, Diabetes.

[69]  J. Schnabel Amyloid: Little proteins, big clues , 2011, Nature.

[70]  K. Ohno-Matsui Parallel findings in age-related macular degeneration and Alzheimer’s disease , 2011, Progress in Retinal and Eye Research.

[71]  V. Hachinski,et al.  Changing perspectives regarding late-life dementia , 2009, Nature Reviews Neurology.

[72]  Ryuichi Morishita,et al.  Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetes , 2010, Proceedings of the National Academy of Sciences.

[73]  S. Gandy,et al.  Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. , 2010, The Mount Sinai journal of medicine, New York.

[74]  C. Glabe,et al.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.

[75]  G. Cole,et al.  The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease , 2007, Experimental Gerontology.

[76]  R. Boado Amplification of blood–brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides , 2001, Neuroscience Research.

[77]  K. Maiese,et al.  Mechanistic insights into diabetes mellitus and oxidative stress. , 2007, Current medicinal chemistry.

[78]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[79]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[80]  M. Goedert,et al.  Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells , 1995, Neuroscience Letters.

[81]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[82]  Dong-Hou Kim,et al.  Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells , 2010, Neurobiology of Disease.

[83]  K. Duff,et al.  Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? , 2004, Briefings in functional genomics & proteomics.

[84]  G. Johnson,et al.  Hyperosmotic stress‐induced apoptosis and tau phosphorylation in human neuroblastoma cells , 2001, Journal of neuroscience research.

[85]  Fatmire Berisha,et al.  Retinal abnormalities in early Alzheimer's disease. , 2007, Investigative ophthalmology & visual science.

[86]  Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. , 1993 .

[87]  W. Klein,et al.  Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease , 2006, Journal of Biological Chemistry.

[88]  J. Luchsinger,et al.  Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms , 2007, The Journal of Neuroscience.